
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 12, 2026, 5:21 PM ET
Fate Therapeutics filed a prospectus supplement for up to $100,000,000 of common stock sales through Leerink Partners as sales agent.
Nasdaq: $FATEBiotechnologyClinical and financing execution
FATE Stock Hub: Fate Therapeutics News, FT819 and RECLAIM-LN
Fate Therapeutics has moved its lupus nephritis program from small exploratory cohorts into a phase 2 study with a defined kidney endpoint. An off-the-shelf product could reduce the logistical burden of a cell therapy, while the kidney trial still has to show a durable response in a larger group. The November conference update adds early evidence from a distinct group with lupus outside the kidneys. September cash, the CIRM award and a newly effective financing shelf give Fate several sources of flexibility as it runs these studies.
Full research report · PDF
Fate Therapeutics ($FATE), research updated November 20, 2026
15 pages on FT819, RECLAIM-LN, cash flow and capital structure. For personal use only: redistribution prohibited.
Next company milestone
December 1–3, 2026 · Piper Sandler healthcare conference
FATE stock at a glance
Chart analysis · JC
Technical chart analysis of $FATE with bull and bear scenarios on JC Just Charts.
Where Fate stands now
The two FT819 trials ask different clinical questions. RECLAIM-LN tests whether FT819 can produce a complete kidney response in a refractory lupus nephritis population. The November American College of Rheumatology (ACR) disclosures ask whether off-the-shelf therapy can be administered with less conditioning and still show clinical activity in selected patients. Those observations are informative in different ways. The kidney study has a more defined population and endpoint, while the experience from the broader phase 1 study contributes to an understanding of safety and delivery. A result from one population cannot simply be assigned to the other. RECLAIM-LN registry · November ACR disclosure
Fate is also operating with a clinical-stage income statement. Collaboration revenue can arrive in particular periods, and government awards can support particular trials. Neither provides a history of product sales. The challenge is to maintain enough cash for the kidney trial and work on the rest of the portfolio while collecting evidence that can support the next financing or development decisions. An event such as a positive interim report is more useful if it comes with patient counts, follow-up and an understandable view of the money still required to reach a more definitive result. September Form 10-Q
Constructive case
A growing kidney-trial cohort yields consistently measured renal responses.
Cautious case
Enrollment or follow-up takes longer, delaying more informative readouts and increasing financing needs.
Latest Fate Therapeutics news
Nov 12, 2026
Fate Therapeutics files $100 million at-the-market stock offering with Leerink Partners
Fate Therapeutics filed a prospectus supplement dated November 12, 2026 for up to $100,000,000 of common stock sales through Leerink Partners LLC as sales agent under a Sales Agreement dated November 5, 2026. The offering uses a shelf registration on Form S-3 (File No. 333-299862), declared effective November 12, 2026. Leerink Partners may receive a commission of up to 3.0% of gross proceeds. As of the prospectus date, 106,155 shares had been sold for aggregate gross proceeds of $176,811.77 under a prior registration statement. The last reported sale price on November 11, 2026 was $1.61 per share.
Nov 10, 2026
Fate Presents FT819 Data at ACR 2026 Showing Lupus Responses Without Conditioning Chemotherapy
Fate Therapeutics presented updated FT819 data at ACR Convergence 2026, with safety described as favorable across 36 patients and no dose-limiting toxicities. 100% (3 of 3) of extrarenal lupus patients treated without conditioning chemotherapy experienced measurable responses, with two achieving DORIS and one achieving LLDAS. Preclinical FT839 data in rheumatoid arthritis were also presented, and the COMPLETE Phase 1/2 basket trial is open for enrollment.
Nov 6, 2026
Wells Fargo lowers Fate Therapeutics price target to $3, maintains Equal-Weight rating
Wells Fargo reduced its price target on Fate Therapeutics to $3 from $3.5. The bank kept its Equal-Weight rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 5, 2026
Fate Therapeutics files $300 million shelf registration on Form S-3
Fate Therapeutics filed a Form S-3 shelf registration on November 5, 2026, covering up to $300,000,000 of common stock, preferred stock, debt securities, warrants and/or units. The filing replaces registration statement No. 333-275402, declared effective on November 27, 2023, which expires on November 27, 2026. It includes a sales agreement prospectus for up to $100,000,000 of common stock with Leerink Partners LLC. Sales under the prior registration may continue until the earlier of the new registration's effective date and May 26, 2027.
Nov 5, 2026
Fate Therapeutics enters $100 million at-the-market sales agreement with Leerink Partners
Fate Therapeutics entered a Sales Agreement with Leerink Partners LLC on November 5, 2026, for an at-the-market offering of up to $100,000,000 in common stock. The company will pay Leerink Partners a commission of up to 3.0% of gross proceeds. The company also terminated its Jefferies LLC Open Market Sale Agreement, under which it sold 2,801,602 shares for gross proceeds of $8.0 million.
Nov 5, 2026
Fate Therapeutics reports third quarter 2026 financial results and business updates
Fate Therapeutics reported financial results and a business update for the quarter ended September 30, 2026. The company had $139.1 million in cash, cash equivalents, and investments, with cash runway expected to mid-2028. RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in lupus nephritis, has enrollment open across 17 active sites, and a $15.0 million CLIN2 grant from CIRM supports the trial.
Catalyst calendar
- November 5, 2026 · September-quarter results. Published.
- November 10, 2026 · ACR clinical update. Published.
- November 12, 2026 · New prospectus supplement. Filed.
- November 18, 2026 · Jefferies investor presentation. Webcast archived.
- December 1–3, 2026 · Piper Sandler investor conference. Scheduled.
Fate Therapeutics deep dive: the full analysis
The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three paths for the primary program
Bull case. RECLAIM-LN enrolls substantially as planned and adds a persuasive series of kidney responses documented under the registry definition. Follow-up supports durability and helps explain how outcomes relate to enrollment characteristics and changes in background treatment. At the same time, Fate develops evidence that selected patients can receive infusions with a practical monitoring plan. Progress on those two questions could justify further investment in the platform as the company considers additional autoimmune indications.
Base case. The study advances across the activated sites, and early sponsor reports offer signs of activity without resolving durability or comparative performance. The choice of endpoint and single-arm design put substantial weight on consistent rules for assessing responses. Management continues to spend on the lead study while testing FT839 separately and using the recent award and available cash to manage the schedule. Future financing, if used, affects how much of any clinical upside belongs to the existing common shares.
Bear case. Enrollment falls behind the company window, safety or monitoring needs complicate outpatient use, or kidney responses prove less consistent as the initial cohort grows. The program could then require additional enrollment, a different study or more follow-up. Those changes would push decisions further into the future and could increase dependence on new capital. The significance of an apparently favorable early result would also diminish if it could not be evaluated with consistent endpoints or diverged from later data.
What would falsify this reading
Evidence of repeated complete renal responses in the registered population, with meaningful follow-up and transparent accounting for missing observations, would carry more weight than an increase in active sites alone. A sponsor report that gives outcomes without showing how many patients reached the assessment visit would leave a material question about the denominator. Severe events requiring extensive monitoring would challenge the delivery case even if a clinical response remained promising. A sustained improvement in operational execution and a clearer financing schedule would weaken the negative case while kidney outcomes mature. RECLAIM-LN registry · September Form 10-Q
02 How lupus nephritis is assessed
Systemic lupus erythematosus can involve multiple organ systems. In lupus nephritis, signs of kidney injury and function have their own assessment. Protein in urine is important, but a complete renal response is usually a composite with a specified proteinuria threshold and a requirement involving kidney function. Some trials add rules for rescue medication or steroid exposure. The measurement matters when a therapy is evaluated in a small cohort. A favorable change on one laboratory measure can precede, or fail to meet, the registered composite outcome. The protocol and assessment time belong next to any reported percentage. RECLAIM-LN registry · Furie et al., New England Journal of Medicine 2020
Belimumab, voclosporin and obinutuzumab have been studied in separate randomized trials in active lupus nephritis. BLISS-LN, AURORA 1 and REGENCY show why background treatment and response definitions are part of interpreting efficacy. Each trial compared a study intervention with its own control under rules specified for that study. Differences in enrollment, contemporary treatment, rescue rules and assessment time prevent direct comparisons of their response percentages with a small refractory subgroup from a cell-therapy study. Their results establish that kidney endpoints and prospective follow-up are important for testing a new approach. Furie et al., New England Journal of Medicine 2020 · Rovin et al., Lancet 2021 · Furie et al., New England Journal of Medicine 2025
Clinical work with CD19-directed cell therapy has provided a rationale for studying B-cell-directed treatment in autoimmune disease. Mackensen and colleagues reported early experience in refractory systemic lupus erythematosus. Müller and colleagues reported follow-up in a case series spanning lupus, inflammatory myositis and systemic sclerosis. Case series can help define questions about remission, B-cell reconstitution and durability in selected patients. They carry no randomized comparison and investigated autologous treatment, so their results cannot be carried directly over to FT819. Kidney endpoints, repeated observations and treatment background remain central to testing Fate’s program on its own evidence. Mackensen et al., Nature Medicine 2022 · Müller et al., New England Journal of Medicine 2024
03 FT819 safety and the August cutoff
Fate’s November 10 release described 36 patients treated across three regimens and four autoimmune disease indications as of August 18. The groups contained 29, six and one patient, respectively, and 30 patients overall had at least three months of follow-up. The company reported no dose-limiting toxicities. The size and maturity of each subgroup are important. The largest safety group supplies the majority of the exposure, while the two smaller groups answer different exploratory questions. Follow-up can still reveal events that were unobserved at the time of the cutoff. November ACR disclosure · FT819-102 registry
| Phase 1 observation | Patients | Interpretation |
|---|---|---|
| All reported treatment, August 18 cutoff | 36 | Sponsor’s updated safety population across regimens and indications |
| At least three months of follow-up | 30 | Longer observation than the full treatment count |
| Outpatient administration | 12 | Nine patients in regimen A and three in regimen B |
| Extrarenal lupus without conditioning | 3 | Two DORIS remissions and one LLDAS at last visit |
| Repeated-treatment regimen | 1 | Individual observation at the time of the cutoff |
Fate reported that eight of the 12 outpatient patients were discharged the day of infusion and the other four the following day. One outpatient experienced grade 2 cytokine release syndrome (CRS) on day four, requiring hospitalization. The event resolved on day five according to the company. The outpatient experience supports the feasibility of administering the product in that setting to selected patients. It also illustrates why a treatment may require monitoring or hospital access after the infusion even if the initial discharge is prompt. With small groups and a nonrandomized setting comparison, similar percentages of reported adverse events should be understood in light of patient selection and the small number of events. November ACR disclosure
The fact that no dose-limiting toxicity was reported applies to the sponsor’s definition and data cutoff. Other treatment-emergent events can still occur. The underlying illnesses, background therapies and observation windows also differ. Future disclosures will be easier to evaluate if they report each event against a clearly defined safety population, explain the follow-up interval and separate events related to the treatment from those observed more generally. That distinction is particularly relevant in a portfolio that treats patients with several different autoimmune diseases under a common early trial. FT819-102 registry
04 Extrarenal activity and its limits
Fate reported three extrarenal lupus patients who received FT819 without conditioning chemotherapy while on stable background therapy under regimen B. At their last reported visits, two met the Definition of Remission in Systemic Lupus Erythematosus (DORIS) and one reached the Lupus Low Disease Activity State (LLDAS). The visits occurred at different points in follow-up. One patient sustained LLDAS through the ninth month, one met DORIS remission at the ninth month, and the third had reached DORIS remission at month three without yet reaching the month-six visit at cutoff. The sponsor reported six patients overall in regimen B, so the three extrarenal patients are a subgroup. November ACR disclosure
The absence of conditioning may matter for patient access and treatment burden if future experience supports its use. It also changes the interpretation of an early signal. Background treatment and the clinical variability of lupus remain plausible contributors, while the small group provides limited information on rare adverse events, outcomes at a consistent visit and durability across organ systems. A future prospective report that includes all eligible patients and assigns a uniform assessment time would provide a stronger comparison than selected experiences reported at their most recent available visits.
DORIS and LLDAS are distinct outcomes. The DORIS task force defined remission using clinical disease activity, a physician assessment threshold and rules for permitted ongoing treatment. van Vollenhoven et al., Lupus Science & Medicine 2021 A low disease activity state is not identical to remission, and neither should be presented as a complete renal response on its own. Comparing outcomes across clinical programs requires the actual prespecified measure, visit and population. The repeated-treatment regimen likewise had one treated person in the ACR cutoff. That patient’s improvement is useful evidence to follow and remains an individual observation. A mature account of later results will need both repeated assessments and a clear description of concomitant therapy. November ACR disclosure
05 RECLAIM-LN is a defined kidney study
The registry describes RECLAIM-LN as a phase 2, open-label, single-arm trial with estimated enrollment of 53. The sponsor reported 17 active sites in its November 5 update and said the first patient had been treated in August. The enrolled population is people with refractory lupus nephritis who meet the study criteria. The primary measure is complete renal response at week 26. The registry requires a urinary protein-to-creatinine ratio below 0.5 g/g, an estimated glomerular filtration rate of at least 85% of baseline or at least 60 mL/min/1.73 m², and no rescue therapy. Because the trial lacks a randomized control group, the observation count, consistency of assessment and durability of the effect will be important to interpretation. RECLAIM-LN registry · November 5 Exhibit 99.1
An active site can screen potential participants. Screening is followed by confirmation that a participant fits the protocol and can proceed to treatment. The site count therefore provides a measure of operating reach, while the number treated and the number reaching six months provide measures of how far the trial has advanced. A site announcement has limited ability to predict when a reliable response denominator will be available. Retention becomes increasingly important after treatment because loss to follow-up, early exit and rescue medication can affect how a single-arm result is interpreted.
The sponsor refers to the study as potentially registrational. That wording describes its intended development path and the role it hopes the trial may play. It does not predetermine the Food and Drug Administration’s view of the evidence, the information needed to support an application or the conditions on any future label. At American Society of Nephrology Kidney Week, Fate described two patients who received the selected conditioning in phase 1 and had reached month six. Each met either the complete or primary-efficacy renal response definition, and the mean urine protein-to-creatinine ratio fell by about half. One participant had reached month 24, with a sustained complete renal response. Fate described broader phase 1 data separately, including patients with a different conditioning regimen. The two-patient observation supplies early context for the phase 2 design but represents a narrower group than the population expected to enroll. The phase 2 population and response definitions provide the appropriate basis for assessing whether those observations recur in a dedicated study. ASN update · RECLAIM-LN initiation
06 The rest of the portfolio
COMPLETE studies FT839 across autoimmune indications. Its phase 1 registry objectives include safety and tolerability. The phase 2 outcome measures differ by indication, including a disease activity measure for rheumatoid arthritis, a vasculitis measure and separate scales for lupus, inflammatory myositis and systemic sclerosis. The basket structure can support development across indications, while the different disease measures limit pooling of efficacy into a single response number. Preclinical findings reported at ACR are a rationale for studying the product in people. The registered study will supply the human clinical observations. COMPLETE registry · November ACR disclosure
The November quarterly update also describes ongoing clinical work with FT836 in solid tumors, including colorectal and non-small-cell lung cancer, and a separate investigator-initiated effort in multiple myeloma. An early reduction in target lesions is a piece of clinical evidence that needs its own denominator, setting, follow-up and response criteria. It is distinct from the autoimmune readouts and should not be aggregated with them in a portfolio response rate. Fate’s next clinical update for the program is a reporting milestone whose scope depends on the patients and follow-up available at the time. November 5 Exhibit 99.1
07 Operating results and the change in cost mix
Fate reported no collaboration revenue in the September quarter of 2026, compared with $1.741 million in the corresponding 2025 quarter. The first nine months still included $3.381 million in collaboration revenue. Quarterly R&D expense was $24.215 million and general and administrative expense was $8.032 million. Total operating expense was $32.247 million. With no revenue in the quarter, that also was the amount of operating loss. Interest income and the remeasurement of share-price appreciation milestone liabilities reduced the net loss to $30.687 million. September 10-Q, consolidated statements of operations
| USD millions | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | 1.741 | 3.381 | 5.277 |
| Research and development expense | 24.215 | 25.838 | 73.305 | 82.404 |
| General and administrative expense | 8.032 | 10.638 | 26.457 | 35.856 |
| Total operating expenses | 32.247 | 36.476 | 99.762 | 118.260 |
| Operating loss | (32.247) | (34.735) | (96.381) | (112.983) |
| Interest income | 1.409 | 2.575 | 4.831 | 8.832 |
| Change in fair value of share-price appreciation milestones | 0.151 | (0.090) | (0.509) | 0.117 |
| Other income | — | — | — | 0.093 |
| Net loss | (30.687) | (32.250) | (92.059) | (103.941) |
The segment expense disclosures show a different pattern from the aggregate operating expense total. Fate reported quarterly clinical program expenses of $7.504 million, against $6.065 million in the year-earlier quarter. Facilities costs decreased to $4.580 million from $6.113 million and personnel costs decreased to $9.652 million from $10.997 million. Clinical program expense rose while total operating expense fell. The product portfolio can therefore require more clinical investment even through a period when the rest of the business absorbs less. These segment figures are an alternative view of the same operating cost base. They should not be added to R&D and general and administrative expense. September 10-Q, segment disclosures
For a development-stage company, the timing of clinical spending can matter as much as the percentage change from last year. Enrollment and site activation can bring a different expense profile from research or a manufacturing campaign, and extended follow-up continues after dosing. The balance between programs will change if COMPLETE or RECLAIM-LN expands faster than expected. It will also change if a promising early cohort motivates more investment before other costs fall. The clinical program line provides a way to monitor that mix alongside the aggregate R&D figure.
Quarterly interest income was lower than a year earlier. The marketable securities portfolio and cash can provide interest income as the company deploys them, but the associated income declines if the pool shrinks or yields change. Changes in estimated fair value are another reason to read operating loss on its own. A reduction in net loss driven by noncash valuation changes provides different information from a lower level of spending on the operations that consume cash. The nine-month operating and cash-flow statements make that distinction particularly clear. September 10-Q
08 Operating cash use, investments and restricted cash
September cash and equivalents were $43.942 million and short-term investments were $95.190 million, for $139.132 million together (Merlintrader calculation). The balance sheet separately reported $5.100 million of restricted cash. At December 31, 2025, Fate had $46.628 million of cash and equivalents, $157.029 million in short-term investments and $1.472 million in long-term investments. The quarter-end liquidity balance is a snapshot before the financing activity identified in later filings and before receipt of the newly awarded grant amounts referred to in the November results. September 10-Q, balance sheets · November 5 Exhibit 99.1
Operating cash use was $82.149 million in the nine months, compared with $82.770 million a year earlier. Property and equipment purchases used an additional $319,000 in 2026. Combined operating and capital spending was $82.468 million, or approximately $9.163 million per month for the nine-month interval (Merlintrader calculation). That average represents the historical period. The company’s forecast uses its own assumptions for grant receipts, expenses and the pace of development. A straight-line extrapolation of prior cash use leaves out changes in milestones, future financing and spending on the lead study. September 10-Q, consolidated statements of cash flows
The cash-flow bridge adds back $8.376 million of depreciation and amortization and $10.145 million of stock-based compensation to the nine-month loss, then reflects changes in working capital and other items. Stock-based compensation was $19.396 million in the year-earlier period, so the improvement in reported earnings reflects a cost category that did not require operating cash at the same time. Net operating cash improved by $621,000 while reported operating expenses fell by $18.498 million (Merlintrader calculation). The difference is material when setting expectations about cash needed to reach a trial milestone. September 10-Q
Investing activity generated $64.979 million net in the 2026 period, including $170.036 million of maturities and $104.738 million of portfolio purchases. Financing activity provided $9.357 million net, including $7.598 million of at-the-market issuance proceeds net of the stated costs and $1.324 million received under an existing FT819-102 award. Together with the operating outflow, these figures reconcile to a $7.813 million decline in cash, cash equivalents and restricted cash. A security maturity can add to the cash line while reducing investments. Looking at cash and investments together gives a better picture of resources available for development than treating the investing inflow as new operating funding. September 10-Q, statements of cash flows
09 The grant, leases and funding horizon
The California Institute for Regenerative Medicine (CIRM) awarded $15 million under its CLIN2 program to support RECLAIM-LN. The award is distinct from the earlier grant supporting FT819-102, which appears in the September cash-flow statement. Fate excludes the newly awarded amount from the September liquidity balance and includes it in the resources supporting management’s runway estimate to mid-2028. Future updates can show the timing of receipts and what portion of program spending those proceeds cover. The award supports a defined development effort and should be followed on its own terms. CIRM award announcement filed with the SEC · November results
Existing CIRM award liabilities were $9.508 million current and $2.377 million noncurrent at September 30. These balances are presented separately from the corresponding operating lease liabilities, which were $5.110 million current and $69.383 million noncurrent. The lease liabilities reflect contractual use of facilities and should remain visible when evaluating future operating commitments. A balance sheet with little conventional borrowing can still carry meaningful fixed cash commitments. Treating credit availability, cash balances, grants and lease obligations as separate line items helps frame funding flexibility. September 10-Q, consolidated balance sheets and commitments
The company’s indicated runway and the planned phases of trial reporting also answer different questions. A company may be able to begin or enroll a trial within its cash horizon and still need financing to maintain follow-up or prepare later regulatory activities. The runway estimate should therefore be compared with a specific milestone and its assumptions. The market may learn about the study in stages. An enrollment announcement, the first availability of six-month results and the primary completion date are distinct. If resources or timing change, each should be reconsidered on its own evidence. November results · RECLAIM-LN registry
10 Common shares, preferred conversion and the two ATM agreements
The September balance sheet reports 121,533,910 common shares and 2,755,086 Class A convertible preferred shares. The cover identifies 121,568,755 common shares outstanding on October 30. Each preferred share is convertible into five common shares, yielding 13,775,430 underlying shares before any applicable limits (Merlintrader calculation). The company also reported approximately 3.9 million shares underlying outstanding pre-funded warrants. These figures identify different categories of capitalization. Outstanding common, preferred conversion equivalents and warrants should be kept separate before evaluating potential dilution. The quarterly weighted average share count used to report loss per share is not a date-specific common share count. September 10-Q · November 5 Exhibit 99.1
| Event or measure | Amount | Reference |
|---|---|---|
| Outstanding common | 121,533,910 | September 30 balance sheet |
| Outstanding common | 121,568,755 | October 30 10-Q cover |
| Class A convertible preferred | 2,755,086 | September 30 balance sheet |
| Common underlying Class A preferred | 13,775,430 | Five per share before limitations |
| Shares issued under the prior Jefferies agreement | 2,801,602 | Historical sales |
| Shares sold under the Leerink agreement using the earlier registration | 106,155 | Reported in the November 12 prospectus |
| Additional potential Leerink offering under the effective shelf | Up to $100 million | November 12 prospectus supplement |
Fate terminated its Jefferies sales agreement on November 5. It had sold 2,801,602 common shares under that agreement and reported $7.598 million of net proceeds in the September cash-flow statement. The November transaction created a separate sales agreement with Leerink. The November 12 prospectus disclosed that Fate already had sold 106,155 shares through Leerink for gross proceeds of $176,811.77 using the November 5 supplement to the earlier registration. It then covered up to $100 million of additional possible sales under the newer registration. The supplement separates completed sales from available capacity, showing what has already raised cash and affected the number of shares. November 12 prospectus supplement · September 10-Q
The new at-the-market program is one possible use of shelf capacity. The $100 million prospectus amount sits within the new shelf registration. When Fate actually sells shares, gross proceeds and net proceeds will differ by commissions and expenses and the common share count will change. The full capacity should be treated as a potential funding source under the disclosed terms. It is separate from the small amount already sold with Leerink under the older registration and from the historical Jefferies sales. The November 12 prospectus explicitly excludes the 106,155 Leerink shares from its referenced September 30 denominator. November 12 prospectus supplement
11 Trading liquidity and ownership measures
Nasdaq’s October 30 settlement report showed 9,972,851 shares sold short and average daily share volume of 1,199,352, corresponding to 8.32 days to cover after rounding. The October 15 observation showed 10,618,410 shares sold short and approximately 8.73 days to cover. Those observations describe outstanding short positions and recent volume at specified reference dates. They do not give real-time positions. Days to cover can increase if average volume falls even when short positions are stable or lower. The financial risk from potential common issuance should be tracked through debt and equity disclosures independently of these trading data. Nasdaq FATE short interest
Beneficial-ownership filings have their own event dates, definitions and share denominators. In a capitalization with convertible preferred and pre-funded warrants, ownership percentages can reflect instruments within a filing’s reporting assumptions. A quarterly common share count and a beneficial ownership percentage answer different questions. Overlapping reporting persons may share the same position, and the disclosed purchase of a security does not automatically imply that the associated common shares have been issued. To understand current equity exposure, the instrument count and conversion conditions provide useful complements to any ownership percentage. September 10-Q · November 12 prospectus supplement
In the Schedule 13D amendment filed November 9, Redmile Group reported beneficial ownership of 19,164,572 shares, or 14.99%, under its disclosed calculation. That percentage uses the October 30 common share count and applies instrument and ownership-limit assumptions for the holder. The filing adds a fund from the same group as a reporting person based on a change to the issuer denominator. The filing attributes the reporting change to the share denominator. November 9 Schedule 13D amendment
12 A calendar with different kinds of milestones
| Date or window | Event | Status |
|---|---|---|
| August 2026 | Sponsor reported the first RECLAIM-LN participant treated | Historical company disclosure |
| September 25, 2026 | Fate announced the new CIRM award for RECLAIM-LN | Award announced |
| October 26, 2026 | Fate published its ASN Kidney Week update | Sponsor disclosure |
| November 5, 2026 | September-quarter results and new Leerink agreement | Reported |
| November 10, 2026 | ACR clinical update on FT819 | Sponsor disclosure |
| November 12, 2026 | Prospectus supplement on the effective shelf | Filed |
| November 18, 2026 | Jefferies investor presentation | Webcast archived |
| December 1–3, 2026 | Piper Sandler healthcare conference | Company-announced conference window |
| By year-end 2026 | Company expected patients to be dosed in COMPLETE | Company expectation |
| First half of 2027 | Next FT836 clinical update | Company expectation |
November 5 results · November 10 ACR release · Conference notice
In RECLAIM-LN, the participant-level primary assessment is at week 26. The estimated primary completion date in the registry is July 2029 and the estimated full study completion is January 2030. These are study-level milestones. The registry estimates do not preclude interim reports, and the timing of an investor event or an earlier company enrollment objective does not change them. A six-month observation for an early participant can become available well before all participants finish the primary assessment. The financing question is whether the company can support operations through those different stages and what evidence will have emerged by the time the cash outlook is revisited. RECLAIM-LN registry · Company financial outlook
The COMPLETE registry likewise distinguishes near-term enrollment from an extended follow-up period. The estimated overall enrollment is 446 across the registered study, not the number treated at the start of phase 1. The phase 1 endpoints include adverse events over follow-up and the phase 2 endpoints use condition-specific measures. Early disclosures may report a single disease cohort or a subset reaching a specific time point. A complete assessment will depend on how enrollment is distributed across groups and how the company presents both clinical activity and safety in each one. COMPLETE registry
13 The Ono collaboration and accounting
Fate’s agreement with Ono Pharmaceutical covers separate product candidates with different rights and performance obligations. Under the agreement and amendments, Ono exercised a development option for Candidate 2. Fate exercised its rights to co-develop and co-commercialize that candidate in the United States and Europe. Payments from Ono for sharing certain joint development costs appear net in research and development expense under the company’s accounting policy. The accounting therefore distinguishes cost sharing for joint development from revenue recorded from research and related obligations elsewhere in the arrangement. September 10-Q, collaboration and option agreement note
The company said the performance obligations for research and nonclinical development of Candidate 3 had been met by June 30. It had received the committed nonclinical funding from Ono through June and described a predefined milestone relevant to the remaining development option. This distinction matters because no collaboration revenue was recorded in the September quarter. The absence of that revenue in one quarter does not determine the status of joint development or whether conditional future payments will come due. For forecasting, committed research fees, recognized revenue, reductions in R&D cost and conditional payments each need a separate line of analysis. September 10-Q
The contract provides for possible future payments associated with clinical, regulatory and commercial events. The filing describes a maximum of $843 million in aggregate per candidate under the stated conditions. Applicable U.S. and European milestone payments are subject to a 50% reduction when Fate elects to co-develop and co-commercialize, and Candidate 3 requires exercise of its option for the subsequent economics described in the agreement. Those figures illustrate contingent contractual opportunity. Cash planning depends on the timing and probability of reaching the underlying milestones and on whether Fate retains any associated expenses or sharing obligations. September 10-Q, Ono arrangement
14 Off-the-shelf access and the evidence needed to support it
An allogeneic platform has a logistics objective as well as a clinical objective. Fate describes FT819 as available from manufactured inventory, unlike an autologous therapy made for a specific patient. Inventory availability can help coordinate a site and a patient, but the overall pathway also includes eligibility, site readiness, clinical monitoring and the ability of patients to return for follow-up. The November outpatient observations speak to how selected patients were treated. They do not show how broadly different sites could deliver care under the same conditions. November 5 results and program descriptions · November 10 ACR update
Other published experience with allogeneic cell therapy in autoimmune disease provides a useful comparison of questions rather than a benchmark for the Fate studies. Wang and colleagues described a small clinical experience with severe myositis and systemic sclerosis. The underlying diseases and treatment program were different from the kidney trial. The publication offers context for why safety, durability and the feasibility of a donor-derived approach have to be evaluated directly. It provides no FT819 outcomes, and it does not resolve whether patients with refractory lupus nephritis will respond under Fate’s protocol. Wang et al., Cell 2024
For investors, a scalable product would need repeatable performance at more than a single center. The first outpatient participant in RECLAIM-LN is an execution milestone because it demonstrates that the trial can use the planned care setting. Data from a broader group would show how often treatment can proceed on schedule and what post-treatment resources are needed. The longer-term clinical test is whether treatment reduces the disease burden under the registered renal endpoint. Operational and clinical progress can move at different speeds, which is why the number of sites, safety events, time in follow-up and actual patient outcomes should be tracked in parallel. RECLAIM-LN initiation and design · RECLAIM-LN registry
Merlintrader Health Score · $FATE
2.70out of 5
Assessed November 20, 2026. Merlintrader calculation: 3.0 × 30% + 3.0 × 30% + 2.0 × 20% + 2.5 × 10% + 2.5 × 10% = 2.70 out of 5.
Red flags to track
- Small early cohorts. The kidney, extrarenal and repeated-treatment observations have distinct denominators and assessment windows.
- Single-arm design. Missing observations, rescue therapy and changes in background care could affect how the phase 2 data are interpreted.
- Delivery and safety. An outpatient infusion can be followed by an event requiring hospitalization.
- Cash use and financing. The operating loss, operating cash outflow, CIRM award and ATM proceeds describe separate parts of the funding picture.
- Potential dilution. Preferred conversion and warrants matter in addition to proceeds from any future primary equity sale.
- Follow-up. Company development windows, individual week-26 assessments and registry completion dates answer different questions.
FATE Stock FAQ: Fate Therapeutics Questions Answered
What does Fate Therapeutics develop?
Fate develops investigational cell therapies for autoimmune disease and cancer. FT819 is in clinical development for lupus and related autoimmune indications. The company has separate programs for additional autoimmune diseases and for cancer. Company pipeline
What is the primary outcome in RECLAIM-LN?
The open-label phase 2 study evaluates complete renal response at week 26. The registry specifies thresholds for urinary protein and kidney function and excludes use of rescue therapy from the definition of response. ClinicalTrials.gov
What has Fate actually raised through the new financing agreement?
The November 12 prospectus reported 106,155 shares sold for $176,811.77 in gross proceeds under the earlier registration using the Leerink agreement. The new supplement authorizes up to $100 million of additional potential sales. November 12 prospectus
What is the next scheduled investor event?
The company’s conference announcement lists the Piper Sandler healthcare conference for December 1–3, 2026. The conference window is separate from the company’s clinical milestones. Fate conference notice
How much cash did Fate report at the end of September?
Cash and equivalents plus short-term investments totaled $139.132 million. The September amount excludes restricted cash and the subsequent cash contemplated under the new CIRM award. September 10-Q · November results
Does the November lupus update test the same population as RECLAIM-LN?
The three patients discussed in the conditioning-free extrarenal subgroup were part of the phase 1 trial. RECLAIM-LN is the separate phase 2 kidney trial with its own eligibility and primary outcome. November ACR update · RECLAIM-LN registry
What is the FT839 program?
FT839 is being studied in the COMPLETE phase 1/2 trial across separately assessed autoimmune indications. The phase 1 part evaluates safety. Later efficacy assessments use disease-specific measures. COMPLETE registry
Sources and scientific literature
- RECLAIM-LN registry
- November ACR disclosure
- September Form 10-Q
- Furie et al., New England Journal of Medicine 2020
- Rovin et al., Lancet 2021
- Furie et al., New England Journal of Medicine 2025
- Mackensen et al., Nature Medicine 2022
- Müller et al., New England Journal of Medicine 2024
- FT819-102 registry
- van Vollenhoven et al., Lupus Science & Medicine 2021
- November 5 Exhibit 99.1
- ASN update
- RECLAIM-LN initiation
- COMPLETE registry
- CIRM award announcement filed with the SEC
- November 12 prospectus supplement
- Nasdaq FATE short interest and volume
- November 9 Schedule 13D amendment
- Webcast archived
- Conference notice
- Wang et al., Cell 2024
- Company pipeline
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $FATE or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Biotechnology companies face clinical, regulatory, manufacturing, enrollment and financing risks, including dilution, and investors can lose capital. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



